Recombinant Human CLEC14A Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human CLEC14A Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human CLEC14A Fc Chimera is coated at 1 µg/mL, 100 μL/well, Recombinant Human VEGF R3/Flt‑4 Fc Chimera (Catalog # 349-F4) binds with an ED₅₀ of 0.8-4.8 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human CLEC14A protein
  

  Human CLEC14A (Glu22-Ala397) Accession # Q86T13	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q86T13
• N-terminal Sequence: Glu22
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 66 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 94-108 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CLEC14A Fc Chimera Protein, CF

• C14orf27
• CEG1
• chromosome 14 open reading frame 27
• CLEC14A
• ClECT and EGF-like domain containing protein
• C-type lectin domain family 14 member A
• C-type lectin domain family 14, member A
• EGF R5
• EGFR5
• EGFR-5
• Epidermal growth factor receptor 5

Background

C-type lectin domain family 14 member A (CLEC14A), also known as epidermal growth factor receptor 5 (EGFR-5), is an approximately 52-kDa member of the C-type lectin domain family that plays a role in angiogenic functions including cell-cell adhesion, endothelial cell migration, and tube formation (1, 2). This tumor endothelial marker is a type I transmembrane protein whose extracellular domain (ECD) domain consists of a 141 amino acid (aa) C-type lectin domain, a 43 aa EGF-like domain, and a sushi-like domain (3). Within the ECD, human CLEC14A shares 67% and 68% sequence identity with mouse and rat CLEC14A, respectively.In endothelial cells, CLEC14A forms a complex with VEGFR-3. Failure in the formation of this complex has been observed to result in the enhanced expression and activity of VEGFR-2 and the downstream signaling (4). By its interaction with VEGFR-3, CLECA4 appears to regulate developmental angiogenesis, lymphangiogenesis, and pathological angiogensis (4). CLEC14A acts in vascular homeostasis by fine-tuning VEGF R2 and VEGF R3 signaling in ECs, suggesting its relevance in the pathogenesis of angiogenesis-related human disorders (4).

1. Jang, J. et al. (2017) Sci. Rep. 7:10666.
2. Mura, M. et al. (2012) Oncogene. 31:293.
3. Zelensky, A. and Gready, J. (2005) FEBS. J. 272:6179.
4. Lee, S. et al. (2017) J. Clin. Invest. 127:457.

Bioinformatics

• Uniprot:
  • Q86T13()